Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?

被引：11

作者：

Breccia, M. ^{[1
]}

Cannella, L. ^{[1
]}

Stefanizzi, C. ^{[1
]}

Carotti, A. ^{[2
]}

Santopietro, M. ^{[1
]}

Alimena, G. ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy

[2] Univ Perugia, Dept Clin & Expt Med, Sect Hematol & Immunol, Hematopoiet Stem Cell Transplant Unit, I-06100 Perugia, Italy

来源：

BONE MARROW TRANSPLANTATION | 2009年 / 44卷 / 05期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITOR; CELLS; PROLIFERATION; ACTIVATION; IMATINIB;

D O I：

10.1038/bmt.2009.20

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

[No abstract available]

引用

页码：331 / 332

页数：2

共 8 条

[1] Acute GvHD: pathogenesis and classification [J].

Ball, L. M. ;

Egeler, R. M. .

BONE MARROW TRANSPLANTATION, 2008, 41 (Suppl 2) :S58-S64

[2] Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens [J].

Fei, Fei ;

Yu, Yingzhe ;

Schmitt, Anita ;

Rojewski, Markus Thomas ;

Chen, Baoan ;

Greiner, Jochen ;

Goetz, Marlies ;

Guillaume, Philippe ;

Doehner, Hartmut ;

Bunjes, Donald ;

Schmitt, Michael .

EXPERIMENTAL HEMATOLOGY, 2008, 36 (10) :1297-1308

[3] Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib [J].

Hochhaus, A. ;

Baccarani, M. ;

Deininger, M. ;

Apperley, J. F. ;

Lipton, J. H. ;

Goldberg, S. L. ;

Corm, S. ;

Shah, N. P. ;

Cervantes, F. ;

Silver, R. T. ;

Niederwieser, D. ;

Stone, R. M. ;

Dombret, H. ;

Larson, R. A. ;

Roy, L. ;

Hughes, T. ;

Mueller, M. C. ;

Ezzeddine, R. ;

Countouriotis, A. M. ;

Kantarjian, H. M. .

LEUKEMIA, 2008, 22 (06) :1200-1206

[4] Important therapeutic targets in chronic myelogenous leukemia [J].

Kantarjian, Hagop M. ;

Giles, Francis ;

Quintas-Cardama, Alfonso ;

Cortes, Jorge .

CLINICAL CANCER RESEARCH, 2007, 13 (04) :1089-1097

[5]

Mustjoki S, 2008, BLOOD, V112, P215

[6] Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells [J].

Nam, Sangkil ;

Williams, Ann ;

Vultur, Adina ;

List, Alan ;

Halla, Kapil ;

Smith, David ;

Lee, Francis Y. ;

Jove, Richard .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) :1400-1405

[7] Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation [J].

Schade, Andrew E. ;

Schieven, Gary L. ;

Townsend, Robert ;

Jankowska, Anna M. ;

Susulic, Vojkan ;

Zhang, Rosemary ;

Szpurka, Hadrian ;

Maciejewski, Jaroslaw P. .

BLOOD, 2008, 111 (03) :1366-1377

[8] Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner [J].

Seggewiss, R ;

Loré, K ;

Greiner, E ;

Magnusson, MK ;

Price, DA ;

Douek, DC ;

Dunbar, CE ;

Wiestner, A .

BLOOD, 2005, 105 (06) :2473-2479

← 1 →